Navigation Links
Tobira Therapeutics Inc. Announces Senior Management Team
Date:6/30/2008

- Senior management team possessing over 130 years of cumulative expertise

-

PRINCETON, N.J. and SAN DIEGO, June 30 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the organization of the company's senior management team. Tobira Therapeutics has been led since its inception in 2006 by James Sapirstein, RPh, MBA as Chief Executive Officer and President. Joining James is Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer, Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and Quality Assurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing and Controls. These additions continue to build the management team with world-class pharmaceutical development experts. "With this senior management team Tobira Therapeutics has more than 130 years of combined pharmaceutical experience, with the majority focused in biotech companies or HIV compounds. We are perfectly positioned to bring novel molecules to market that will play an important role in the treatment of HIV infection".

Dr. Palleja is the Chief Medical Officer, responsible for the overall clinical development of the Tobira Therapeutics portfolio. Sandra joined Tobira from Shionogi USA, where she lead numerous clinical programs as Vice President of Clinical Development in several therapeutic categories including an HIV joint venture with GSK. Prior to her years at Shionogi, Sandra gained additional experience from both Triangle Pharmaceutics and Hoffman-LaRoche, where she helped develop a variety of antivirals for HIV and hepatitis including FTC, DAPD, ganciclovir, and saquinavir. Prior to her career in industry, she was the Director of the Infectious Diseases Clinic at St. Vincent's Hospital and Medical Center of New York City during the mid to late 90's. Prior to her years at St. Vincent's, Sandra was an Associate Professor of Medicine, served as the Primary Care Liason to the AIDS Team at the Albert Einstein College of Medicine and Bronx Municipal Hospital Center. From 1989-1993, she also served as Consultant to the AIDS Institute, NYSDOH and the Federally Funded Ryan White Title III Program. She earned her MD from Boston University School of Medicine.

Ms. Shashlo joined Tobira from Incyte Corporation where she held a similar role as the VP of Regulatory Affairs and Quality Assurance. Prior to Incyte, Angie spent several years working with start-up companies such as Genaera, Vitagen and Ligand in a variety of roles including Project Management. Angeline spent many years working for larger pharmaceutical companies such as Wyeth and Upjohn during the first half of her 25-year career in positions of increasing responsibility. Angie received her Bachelor of Science in Pharmacy from the University of Michigan.

Dr. Rheingold brings over 29 years of experience in new product scale-up, formulation development and manufacturing to Tobira Therapeutics. Jay has successfully brought over 25 products to market during his tenure at Lederle, Hoffman-LaRoche, Bristol-Myers Squibb and Organon pharmaceutical companies. He received his doctorate in Pharmaceutical Sciences from the University of Connecticut. Jay joins Tobira from Barrier Therapeutics, where he held the position of Vice-President.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

Contact:

Tobira Therapeutics Inc.

James Sapirstein CEO and President Tobira Therapeutics, Inc.

jsapirstein@tobiratherapeutics.com

Tel: 609-897-1102

http://www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
5. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
6. Barrier Therapeutics to Merge Into Stiefel Laboratories
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):